1212 Amsterdam Avenue
11 articles with Columbia University
The initiative, a partnership between non-profit biotech company n-Lorem and Columbia University, focuses on developing personalized experimental ASO medicines for nano-rare ALS patients.
Pfizer apparently hasn't begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
n-Lorem announced today the formation of Silence ALS, an initiative that aligns Columbia University and n-Lorem in support of the characterization of nano-rare amyotrophic lateral sclerosis (ALS) patients.
The FDA has stated that GSK and Vir’s COVID-19 treatment sotrovimab is no longer authorized to be used for the condition because of its low efficacy against Omicron sub-variant BA.2.
Researchers have developed a new form of UV light that is safe for people but decreased the level of indoor airborne microbes by more than 98% in less than five minutes.
Researchers may have found a potential treatment for congenital heart defects in a surprising source: an over-the-counter cough suppressant. Know more here.
High Performing Algorithm To Translate Paralyzed Patients' Thoughts Into Real-Time Prosthetic Movements
Blackrock Neurotech, the leader in brain-computer interface technology, has signed an exclusive license for Columbia University's neural decoder MINT.
Over the past ten years, Tonix's pipeline has evolved to also comprise assets in biodefense, immunology and cancer therapeutics.
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
- The new agreements mean BridgeBio has collaborations with 25 leading academic institutions focused on genetic disease and precision oncology
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease Agreement Provides for Option to License Alzheimer’s Therapeutic
Silo Pharma, Inc. today announced that it has entered into a sponsored research agreement with Columbia University pursuant to which Silo has been granted an option to license certain assets currently under development, including Alzheimer’s disease.